Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 04, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Rumpus Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma
Details : Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.
Product Name : Kinenza
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and will be able to be commercialized and supplied within Australia.
Product Name : Zolpimist
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 30, 2020
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable